company background image
1760 logo

Panion & Bf Biotech TWSE:1760 Stock Report

Last Price

NT$93.80

Market Cap

NT$8.0b

7D

-1.3%

1Y

-10.7%

Updated

02 Sep, 2024

Data

Company Financials +

Panion & Bf Biotech Inc.

TWSE:1760 Stock Report

Market Cap: NT$8.0b

1760 Stock Overview

A biotechnology pharmaceutical company, manufactures, distributes, and trades in western medicines, cosmetics, testing reagents, food products, and chemicals in Taiwan, the United States, China, Hong Kong, and internationally.

1760 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance4/6
Financial Health5/6
Dividends0/6

Panion & Bf Biotech Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Panion & Bf Biotech
Historical stock prices
Current Share PriceNT$93.80
52 Week HighNT$125.50
52 Week LowNT$76.20
Beta0.27
11 Month Change0.11%
3 Month Change-2.39%
1 Year Change-10.67%
33 Year Change24.40%
5 Year Change8.31%
Change since IPO728.21%

Recent News & Updates

Is Panion & Bf Biotech (TWSE:1760) A Risky Investment?

Aug 13
Is Panion & Bf Biotech (TWSE:1760) A Risky Investment?

Recent updates

Is Panion & Bf Biotech (TWSE:1760) A Risky Investment?

Aug 13
Is Panion & Bf Biotech (TWSE:1760) A Risky Investment?

Here's Why Panion & Bf Biotech (TPE:1760) Has A Meaningful Debt Burden

Apr 07
Here's Why Panion & Bf Biotech (TPE:1760) Has A Meaningful Debt Burden

Is Panion & Bf Biotech Inc. (TPE:1760) A Strong Dividend Stock?

Mar 03
Is Panion & Bf Biotech Inc. (TPE:1760) A Strong Dividend Stock?

Introducing Panion & Bf Biotech (TPE:1760), A Stock That Climbed 47% In The Last Three Years

Feb 04
Introducing Panion & Bf Biotech (TPE:1760), A Stock That Climbed 47% In The Last Three Years

Are Panion & Bf Biotech Inc.'s (TPE:1760) Mixed Financials Driving The Negative Sentiment?

Jan 09
Are Panion & Bf Biotech Inc.'s (TPE:1760) Mixed Financials Driving The Negative Sentiment?

Panion & Bf Biotech (TPE:1760) Has A Somewhat Strained Balance Sheet

Dec 14
Panion & Bf Biotech (TPE:1760) Has A Somewhat Strained Balance Sheet

Shareholder Returns

1760TW PharmaceuticalsTW Market
7D-1.3%0.4%0.6%
1Y-10.7%13.8%32.9%

Return vs Industry: 1760 underperformed the TW Pharmaceuticals industry which returned 13.8% over the past year.

Return vs Market: 1760 underperformed the TW Market which returned 32.9% over the past year.

Price Volatility

Is 1760's price volatile compared to industry and market?
1760 volatility
1760 Average Weekly Movement5.2%
Pharmaceuticals Industry Average Movement5.4%
Market Average Movement5.6%
10% most volatile stocks in TW Market9.3%
10% least volatile stocks in TW Market3.0%

Stable Share Price: 1760 has not had significant price volatility in the past 3 months.

Volatility Over Time: 1760's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1976n/aTsung-Ming Chiangwww.pbf.com.tw

Panion & Bf Biotech Inc., a biotechnology pharmaceutical company, manufactures, distributes, and trades in western medicines, cosmetics, testing reagents, food products, and chemicals in Taiwan, the United States, China, Hong Kong, and internationally. The company offers products in the areas of personal cleaning, medical aesthetic, kidney-specific, pet care, and delay aging, as well as disease treatment, prevention, and diagnosis. It provides body cleansing, emollient lotion, hair cleansing, in-hospital care, minimally invasive, frozen age care and maintenance, oral medication, skin and hand disinfection, respiratory and gastrointestinal tract, and salon products; and pet health products, including surgical and skin prescriptions.

Panion & Bf Biotech Inc. Fundamentals Summary

How do Panion & Bf Biotech's earnings and revenue compare to its market cap?
1760 fundamental statistics
Market capNT$8.04b
Earnings (TTM)NT$101.27m
Revenue (TTM)NT$2.01b

79.4x

P/E Ratio

4.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1760 income statement (TTM)
RevenueNT$2.01b
Cost of RevenueNT$951.11m
Gross ProfitNT$1.06b
Other ExpensesNT$956.80m
EarningsNT$101.27m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)1.18
Gross Margin52.66%
Net Profit Margin5.04%
Debt/Equity Ratio39.1%

How did 1760 perform over the long term?

See historical performance and comparison

Dividends

1.6%

Current Dividend Yield

127%

Payout Ratio